REMAP-CAP (IL-6)
2021
Tocilizumab or Sarilumab in Critically Ill COVID-19
In 803 critically ill ICU COVID-19 patients within 24 h of organ support, tocilizumab or sarilumab improved organ-support-free days and hospital survival versus control.
Result
Primary endpoint: Organ-support-free days at 21 days
Median organ-support-free days 10 (tocilizumab) and 11 (sarilumab) vs 0 (control); adjusted cumulative OR 1.64 (95% CrI 1.25-2.14) and 1.76 (95% CrI 1.17-2.91). Pooled 90-day survival HR 1.61 (95% CrI 1.25-2.08).
- Subtopic
- IL-6 antagonists
- Design
- Adaptive platform RCT (REMAP-CAP)
- Relevance
- Important: one of several pillars.
- Source
- REMAP-CAP Investigators. N Engl J Med. 2021;384(16):1491-1502.doi 10.1056/NEJMoa2100433
Discussion & critique
Together with RECOVERY-Toci, the basis for routine IL-6 blockade in deteriorating COVID-19.